<DOC>
	<DOC>NCT01727232</DOC>
	<brief_summary>The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .</brief_summary>
	<brief_title>Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia</brief_title>
	<detailed_description>Every adult (age â‰¥ 18 years) seen in one of the 3 participating centre (dijon, Marseille, Mondor) over a 7-year period (2005-2012) with a definite diagnosis of primary ITP according to the American Society Hematology guidelines who received RTX regardless the regimen could be included.</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Primary ITP Age &gt; 18 years Secondary ITP Age &lt; 18 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ITP</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Anti-CD20</keyword>
	<keyword>Regimen</keyword>
</DOC>